Skip to content
OpenCapital
Get started

AngioDynamics ANGO Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$6.8B+4.1%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.02B+49.0%
TFX
TeleflexTFX
$329.55M+16.8%
Stryker logo
StrykerSYK
$2.88B+24.1%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$488.08M+23.4%
ICU Medical logo
ICU MedicalICUI
$288.33M-0.5%

Other financials

Income statement

See full
Revenue$78.4M+8.9%
Gross profit$41.5M+6.7%
Operating income-$13.0M-29.8%
Net income-$8.1M-83.4%
EPS (diluted)-$0.19-72.7%

Balance sheet

See full
Total debt$7.9M+10.2%
Total equity$173.4M-6.7%
Total assets$260.7M-8.7%

Cash flow

See full
Operating cash flow-$3.1M+76.4%
CapEx$1.0M-43.5%
Free cash flow-$4.1M+72.4%

Valuation

See full
Market cap$564.42M+38.7%
Enterprise value$534.51M+48.0%
P/S1.8×+0.4×

Profitability

See full
Gross margin54.3%-0.1pp
Operating margin-11.3%-2.9pp
Net margin-10%-2.4pp
FCF margin5.5%—

Returns & leverage

See full
Return on equity-17.5%-2.2pp
Debt / equity0×0.0×
Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AngioDynamics's cash & equivalents?
AngioDynamics (ANGO) reported cash & equivalents of $37.81M in Q4 2025.
How has AngioDynamics's cash & equivalents changed year-over-year?
AngioDynamics's cash & equivalents decreased by 15.5% year-over-year, from $44.76M to $37.81M.
What is the long-term trend for AngioDynamics's cash & equivalents?
Over 4 years (2021 to 2025), AngioDynamics's cash & equivalents has grown at a 3.8% compound annual growth rate (CAGR), from $48.16M to $55.89M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.